News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
1The new U.S. earnings season kicks off this week: U.S.-Iran negotiations break down, can bank giants' earnings boost market sentiment?2Oil Surpasses $100 After U.S. Navy Closes Strait of Hormuz - How Serious Is the Threat to Supply?
Viking Holdings (VIK) Surpasses Q4 Expectations for Earnings and Revenue
101 finance·2026/03/03 14:13
Daxor Insiders Are Purchasing: However, What Could the CEO's Previous Sale Indicate?
101 finance·2026/03/03 14:12
Neuronetics Q4 Results: Is This a Sell-the-News Opportunity or a Chance to Buy the Dip?
101 finance·2026/03/03 14:09
Palantir's 13% Surge: A Defense Rotation or a Sustained Flow?
101 finance·2026/03/03 14:09
Gas prices jump by 30% again after Qatar halts additional output
101 finance·2026/03/03 14:09
T Unveils Intelligent Manufacturing Solution: Can It Enhance Future Growth?
101 finance·2026/03/03 13:57
Oracle’s AI Pipeline Expands: Can Continued Growth Be Expected?
101 finance·2026/03/03 13:48
NXXT Spikes on NeutronX Deal But Stalls at Key Resistance
101 finance·2026/03/03 13:48
Flash
09:00
A Certain Crude Oil Top Holder Shifts to Storage Sector, Two-Week Unrealized Gain Reaches $1.15 MillionBlockBeats News, April 13, according to Hyperinsight monitoring, the largest short seller of crude oil on Hyperliquid at the end of March (0xa65) exited the crude oil short position at a loss last week, briefly went long to attempt a bottom fishing, and closed the position again yesterday, completely exiting the crude oil market.
Currently, this address has shifted its position focus entirely to the U.S. stock storage sector, retaining only two long positions opened at the beginning of the month for MU (Micron Technology) and SNDK (SanDisk), with a total position size of $5.4 million, and the current floating profit has reached $1.15 million.
08:57
UBS lowers ServiceNow target price to $100GLONGHUI April 13｜UBS has lowered ServiceNow's target price from $170 to $100 and downgraded its rating from "Buy" to "Neutral". (GLONGHUI)
08:48
US Stock Movement | Replimune plunges over 56% in pre-market trading as RP1's listing application is rejected by the FDA againGlonghui, April 13 — Biotechnology company Replimune (REPL.US) fell more than 56% to $2.09 before market open. According to reports, Replimune’s core drug RP1 failed to obtain FDA approval. On April 10, 2026, the FDA issued a Complete Response Letter (CRL), officially rejecting the drug’s marketing application. The FDA rejected the RP1 application once again, citing insufficient clinical trial design and data inadequate to support its efficacy. Although the drug itself showed decent efficacy and safety data, the FDA has set stricter evidence standards for the “accelerated approval” pathway. This marks the second major setback for RP1 since its first rejection in July 2025.
News